Navigation

Thursday, May 9th 2019

08.10 – 08.15

Welcome

08.10 – 08.15
Opening of the Meeting

Paolo Ferrari, Chief Medical Officer, Ente Ospedaliero Cantonale

08.15 – 09.35

World Epidemics – Joint Session with ESC Working Group on Cardiovascular Pharmacotherapy

Chairpersons: Thomas Kahan (Stockholm, SE), Antoni Martinez-Rubio (Barcelona, ES), Hector Ventura (Miami, US), Luca Gabutti (Bellinzona, CH)

08.15 – 08.30
Dyslipidemia – new challenges and how to achieve targets

Heinz Drexel (Feldkirch, AT)

08.30 – 08.45
Hypertension management in year 2019. Pending Issues

Gianfranco Parati (Milan, IT)

08.45 – 09.00
The management of patients with diabetes and heart failure: the start of a new era?

Felipe Martinez (Cordoba, AR)

09.00 – 09.15
Obesity after smoking cessation – rationale of a complex interplay

Koji Hasegawa (Kyoto, JP)

09.15 – 09.35
Discussion

09.35 – 10.35

A Changing Paradigm in Management of Dyslipidemia

Chairpersons: Koji Hasegawa (Kyoto, JP), Alexandre Fredenrich (Bellinzona, CH / Nice, FR ), Heinz Drexel (Feldkirch, AT)

09.35 – 09.50
The discovery of PCSK9

Catherine Boileau (Paris, FR)

09.50 – 10.05
Opportunities and barriers for the successful clinical utilisation of PCSK9

Michel Farnier (Dijon, FR)

10.05 – 10.20
PCSK9 – Effects beyond LDL lowering

Alberico L. Catapano (Milan, IT)

10.20 – 10.35
Discussion

10.35 – 11.05

Coffee Break

11.05 – 12.05

Anti-Inflammatory Treatment in Coronary Artery Disease

Chairpersons: Filippo Crea (Rome, IT), Giuseppe Vassalli (Lugano, CH), Alberto Lorenzatti (Cordoba, AR), Konstantinos Koskinas (Bern, CH)

11.05 – 11.20
The rationale for anti-inflammatory treatment

Peter Libby (Boston, US)

11.20 – 11.35
The clinical evidence: targeting interleukin-1β: the CANTOS trial

Luigi M. Biasucci (Rome, IT)

11.35 – 11.50
A word of caution

Juan Carlos Kaski (London, GB)

11.50 – 12.05
Discussion

12.05 – 12.30

KEY LECTURE – CARDIOVASCULAR PHARMACOTHERAPY IN THE ELDERLY
LECTURE SPONSORED BY Daiichi Sankyo

Chairpersons: Juan Carlos Kaski (London, GB), Edgardo Escobar (Santiago, CL), Alessandro Ceschi (Lugano, CH)

12.05 – 12.20
Polypharmacy: what the clinical cardiologist should be aware of

Stephan Krähenbühl (Basel, CH)

12.20 – 12.30
Discussion

12.30 – 13.30

Lunch

12.30 – 13.30

PCSK9 INHIBITORS: HOW TO BRIDGE FROM HIGH CLINICAL VALUE TO ACCESS FOR PATIENTS?
Satellite Working Lunch Session - organized by AMGEN

Chairpersons: Augusto Gallino (Bellinzona, CH), Stefan Windecker (Bern, CH), Walter Riesen (Diessenhofen, CH)

12.30 – 12.35
Welcome and Introduction

Augusto Gallino (Bellinzona, CH), Stefan Windecker (Bern, CH)

12.35 – 12.50
PCSK9 Inhibitors: Discrepancies between science and reimbursement in secondary prevention

Christian Mueller (Basel, CH)

12.50 – 13.05
Optimizing cardiovascular outcomes with PCSK9 Inhibitors: start now before a potential next MI or stroke

François Mach (Geneva, CH)

13.05 – 13.15
Patients to consider for PCSK9 Inhibitor treatment

Isabella Sudano (Zurich, CH), Konstantinos Koskinas (Bern, CH)

13.15 – 13.30
Panel Discussion and Closing Remarks

13.30 – 14.20

Medical vs Invasive Treatment Strategies in Stable Coronary Artery Disease: Debate Session

Chairpersons: Juan Carlos Kaski (London, GB), Olivier Muller (Lausanne, CH), Koji Hasegawa (Kyoto, JP), Marco Moccetti (Lugano, CH)

13.30 – 13.45
Are percutaneous coronary interventions needed in patients with stable angina?

Filippo Crea (Rome, IT)

13.45 – 14.00
Missed opportunities for successful myocardial revascularisation in stable coronary artery disease

Stefan Windecker (Bern, CH)

14.00 – 14.05
Rebuttal Filippo Crea (Rome, IT)

14.05 – 14.10
Rebuttal Stefan Windecker (Bern, CH)

14.10 – 14.20
Discussion

14.20 – 15.20

Emerging Indications for New Oral Anticoagulation in Stable Coronary Artery Disease

Chairpersons: Gheorghe Dan (Bucharest, RO), Antoni Martinez-Rubio (Barcelona, ES), Roberto Corti (Zurich, CH)

14.20 – 14.35
Rivaroxaban; from research to medicine

Elisabeth Perzborn (Wuppertal, DE)

14.35 – 14.50
NOACs in acute coronary syndrome and after coronary stent in patients with atrial fibrillation

Giovanni B. Pedrazzini (Lugano, CH)

14.50 – 15.05
Advances in anticoagulant therapies; from Aspirin to NOACs

Salim Yusuf (Hamilton, CA)

15.05 – 15.20
Discussion

15.20 – 15.50

Coffee break

15.50 – 16.35

Antithrombotic Treatment in Acute Coronary Artery Disease in the World of Emerging Stents

Chairpersons: Felipe Martinez (Cordoba, AR), Doreen Tan (Singapore, SGP), Daniel Suerder (Lugano, CH)

15.50 – 16.05
State of art secondary prevention with antithrombotics

Marco Valgimigli (Bern, CH)

16.05 – 16.20
Will emerging stents simplify antithrombotic treatment?

Marco Roffi (Geneva, CH)

16.20 – 16.35
Discussion

16.35 – 17.30

PCSK-9 INHIBITION: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL
A SANOFI SYMPOSIUM

Chairpersons: Heinz Drexel (Feldkirch, AT), Alvaro Sosa-Liprandi (Buenos Aires, AR), Stefan Windecker (Bern, CH)

16.35 – 16.50
Effect of Alirocumab on cardiovascular events and all-cause mortality

Christian Mueller (Basel, CH)

16.50 – 17.05
Advances in targeting LDL and Lp(a)- Causal Risk Factors for Atherosclerosis

Peter Libby (Boston, US)

17.05 – 17.20
Patients to consider for Aliricumab treatment

Alberico L. Catapano (Milan, IT)

17.20 – 17.30
Discussion

17.30 – 18.00

Distinguished Eugene Braunwald Lecture

Chairpersons: Juan Carlos Kaski (London, GB), Filippo Crea (Rome, IT), Ludwig K. von Segesser (Lausanne, CH), Augusto Gallino (Bellinzona, CH)

17.30 – 17.50
The Inclisiran (RNAi of PCSK9) trial: an avenue for postponing CAD until the age of 100?

Eugene Braunwald (Boston, US)

17.50 – 18.00
Discussion

18.00 – 18.30

Neufeld Lecture

Chairpersons: Juan Carlos Kaski (London, GB), Tiziano Moccetti (Lugano, CH), Koji Hasegawa (Kyoto, JP), Augusto Gallino (Bellinzona, CH)

The Polypill: A simple, inexpensive approach to reduce mortality and morbidity worldwide

Salim Yusuf (Hamilton, CA)